The design and synthesis of a potent glucagon receptor antagonist with favorable physicochemical and pharmacokinetic properties as a candidate for the treatment of type 2 diabetes mellitus |
| |
Authors: | Angel Guzman-Perez Jeffrey A Pfefferkorn Esther CY Lee Benjamin D Stevens Gary E Aspnes Jianwei Bian Mary T Didiuk Kevin J Filipski Dianna Moore Christian Perreault Matthew F Sammons Meihua Tu Janice Brown Karen Atkinson John Litchfield Beijing Tan Brian Samas William J Zavadoski Judith Treadway |
| |
Affiliation: | Pfizer Wordwide Research and Development, Eastern Point Road, Groton, CT 06442, USA |
| |
Abstract: | A novel and potent small molecule glucagon receptor antagonist for the treatment of diabetes mellitus is reported. This candidate, (S)-3-4-(1-{3,5-dimethyl-4-4-(trifluoromethyl)-1H-pyrazol-1-yl]phenoxy}butyl)benzamido]propanoic acid, has lower molecular weight and lipophilicity than historical glucagon receptor antagonists, resulting in excellent selectivity in broad-panel screening, lower cytotoxicity, and excellent overall in vivo safety in early pre-clinical testing. Additionally, it displays low in vivo clearance and excellent oral bioavailability in both rats and dogs. In a rat glucagon challenge model, it was shown to reduce the glucagon-elicited glucose excursion in a dose-dependent manner and at a concentration consistent with its rat in vitro potency. Its properties make it an excellent candidate for further investigation. |
| |
Keywords: | Glucagon receptor antagonist Diabetes mellitus Physicochemical properties |
本文献已被 ScienceDirect 等数据库收录! |
|